DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma, Open-Angle; Ocular Hypertension

Intervention: 0.15% Brimonidine Tartrate (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan


This study will evaluate 0. 15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.

Clinical Details

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Diagnosis of open-angle glaucoma or ocular hypertension

Exclusion Criteria:

- Used Alphagan® in previous 3 months

Locations and Contacts

Shanghai, China
Additional Information

Starting date: July 2010
Last updated: June 24, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017